These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28551636)

  • 21. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
    Juengel E; Kim D; Makarević J; Reiter M; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2015 Feb; 19(2):430-41. PubMed ID: 25444514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
    Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
    EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.
    Merhautova J; Hezova R; Poprach A; Kovarikova A; Radova L; Svoboda M; Vyzula R; Demlova R; Slaby O
    Biomed Res Int; 2015; 2015():941980. PubMed ID: 26064968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.
    Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
    J Cell Mol Med; 2024 May; 28(9):e18329. PubMed ID: 38693863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients.
    Armesto M; Nemours S; Arestín M; Bernal I; Solano-Iturri JD; Manrique M; Basterretxea L; Larrinaga G; Angulo JC; Lecumberri D; Iturregui AM; López JI; Lawrie CH
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.
    Gobe GC; Ng KL; Small DM; Vesey DA; Johnson DW; Samaratunga H; Oliver K; Wood S; Barclay JL; Rajandram R; Li L; Morais C
    Biochem Biophys Res Commun; 2016 Apr; 473(1):47-53. PubMed ID: 26995091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma.
    Su Z; Chen D; Zhang E; Li Y; Yu Z; Shi M; Jiang Z; Ni L; Yang S; Gui Y; Ye J; Lai Y
    Mol Med Rep; 2015 Jul; 12(1):1535-43. PubMed ID: 25815776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes.
    Papadopoulos EI; Yousef GM; Scorilas A
    Biomed Pharmacother; 2015 Mar; 70():33-40. PubMed ID: 25776476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma.
    He J; He J; Min L; He Y; Guan H; Wang J; Peng X
    Int J Cancer; 2020 Feb; 146(4):1052-1063. PubMed ID: 31259424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA Expression Profiling in Clear Cell Renal Cell Carcinoma: Identification and Functional Validation of Key miRNAs.
    He H; Wang L; Zhou W; Zhang Z; Wang L; Xu S; Wang D; Dong J; Tang C; Tang H; Yi X; Ge J
    PLoS One; 2015; 10(5):e0125672. PubMed ID: 25938468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8.
    Liu F; Chen N; Xiao R; Wang W; Pan Z
    Biochem Biophys Res Commun; 2016 Nov; 480(1):87-93. PubMed ID: 27717821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feedback activation of GATA1/miR-885-5p/PLIN3 pathway decreases sunitinib sensitivity in clear cell renal cell carcinoma.
    Yao D; Xia S; Jin C; Zhao W; Lan W; Liu Z; Xiu Y
    Cell Cycle; 2020 Sep; 19(17):2195-2206. PubMed ID: 32783497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells.
    Nishikawa R; Osaki M; Sasaki R; Ishikawa M; Yumioka T; Yamaguchi N; Iwamoto H; Honda M; Kabuta T; Takenaka A; Okada F
    Oncol Rep; 2020 Nov; 44(5):1810-1820. PubMed ID: 32901843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma.
    Park SE; Kim W; Hong JY; Kang D; Park S; Suh J; You D; Park YY; Suh N; Hwang JJ; Kim CS
    Sci Rep; 2022 Mar; 12(1):3537. PubMed ID: 35241735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of Metabolomic Changes in Sunitinib-Resistant Human Renal Carcinoma 786-O Cells by Capillary Electrophoresis-Time of Flight Mass Spectrometry.
    Hatakeyama H; Fujiwara T; Sato H; Terui A; Hisaka A
    Biol Pharm Bull; 2018; 41(4):619-627. PubMed ID: 29607935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue.
    Vitruk Yu V; Semko SL; Voylenko OA; Pikul MV; Borikun TV; Zadvornyi TV; Yalovenko TM; Stakhovsky EO; Rossylna OV
    Exp Oncol; 2021 Jun; 43(2):98-103. PubMed ID: 34190510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
    Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
    Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of miR-27a-3p is an independent predictive factor for recurrence in clear cell renal cell carcinoma.
    Nakata W; Uemura M; Sato M; Fujita K; Jingushi K; Ueda Y; Kitae K; Tsujikawa K; Nonomura N
    Oncotarget; 2015 Aug; 6(25):21645-54. PubMed ID: 26046464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lefty A is involved in sunitinib resistance of renal cell carcinoma cells via regulation of IL-8.
    Cui N; Han Q; Cao Q; Wang K; Zhou X; Hou P; Liu C; Chen L; Xu L
    Biol Chem; 2021 Sep; 402(10):1247-1256. PubMed ID: 34363384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.
    Gao H; Jiang Q; Han Y; Peng J; Wang C
    Cell Biochem Biophys; 2015 Mar; 71(2):757-64. PubMed ID: 25260394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.